It is very uncertain whether buried (subcutaneous) changes peritonitis rate (patient‐months) compared with non‐buried catheter (very low certainty).
It is very uncertain whether buried (subcutaneous) changes exit‐site/tunnel infection rate (patient‐months) compared with non‐buried catheter (very low certainty).
It is very uncertain whether buried (subcutaneous) changes technique failure compared with non‐buried catheter (very low certainty).
Hypothermic machine perfusion leads to lower DGF compared with static cold storage (high certainty).
Hypothermic machine perfusion showed no clear difference in treated acute rejection in the first year compared with static cold storage (low certainty).
Hypothermic machine perfusion leads to lower DGF: DCD group compared with static cold storage (high certainty).
Hypothermic machine perfusion leads to lower DGF: DBD group compared with static cold storage (high certainty).
Hypothermic machine perfusion leads to lower DGF: modern era studies compared with static cold storage (high certainty).
The review found no eligible studies for this question.
Hypothermic machine perfusion showed no clear difference in PNF compared with static cold storage (high certainty).
Hypothermic machine perfusion showed no clear difference in one year patient survival compared with static cold storage (low certainty).
It is very uncertain whether mycophenolate mofetil (MMF) changes death compared with IV cyclophosphamide (CPA) (very low certainty).
Mycophenolate mofetil (MMF) + tacrolimus (TAC) showed no clear difference in partial renal remission compared with IV cyclophosphamide (CPA) (low certainty).
Mycophenolate mofetil (MMF) + tacrolimus (TAC) may leads to higher stable kidney function compared with IV cyclophosphamide (CPA) (low certainty).
It is very uncertain whether azathioprine (AZA) changes death compared with mycophenolate mofetil (MMF) (very low certainty).
It is very uncertain whether azathioprine (AZA) changes ESKD compared with mycophenolate mofetil (MMF) (very low certainty).
Azathioprine (AZA) probably leads to higher renal relapse compared with mycophenolate mofetil (MMF) (moderate certainty).
Azathioprine (AZA) may leads to higher doubling of serum creatinine compared with mycophenolate mofetil (MMF) (low certainty).
Azathioprine (AZA) showed no clear difference in major infection compared with mycophenolate mofetil (MMF) (low certainty).